Stock 688336 SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

Equities

688336

CNE1000062X2

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-05-30 EDT 		5-day change 1st Jan Change
22.52 CNY +1.30% Intraday chart for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd -0.22% +0.04%
04-25 Sunshine Guojian Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-21 Sunshine Guojian Pharmaceutical's Profit Surges Sixfold in 2023 MT

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 43.31 times its estimated earnings per share for the ongoing year.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD Stock Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
+0.04% 1.89B -
CSL LIMITED Stock CSL Limited
-2.29% 89.38B
A-
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-3.95% 37.92B
A-
BIOGEN INC. Stock Biogen Inc.
-13.07% 32.04B
B-
UCB Stock UCB
+63.05% 26.03B
A
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-22.14% 14.14B
C
INCYTE CORPORATION Stock Incyte Corporation
-7.96% 12.88B
B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.33% 11.77B
D+
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-46.33% 10.85B
B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.77% 8.92B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. 688336 Stock
  4. Ratings Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd